Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Center, Korea
NRG Oncology
University of Kentucky
Mayo Clinic
Janssen Research & Development, LLC
City of Hope Medical Center
University of Southampton
Columbia University